Literature DB >> 1718128

Late-infantile Gaucher disease in a child with myoclonus and bulbar signs: neuropathological and neurochemical findings.

N Conradi1, M Kyllerman, J E Månsson, A K Percy, L Svennerholm.   

Abstract

Clinical, neurochemical and neuropathological findings on a case of late-infantile Gaucher disease with oculomotor apraxia, progressive myoclonus and prominent bulbar signs are reported. There was a marked increase in glucosylceramide in cerebral cortex and cerebellum; the increase was more in the range of that seen in the Norrbottnian type III than in type II Gaucher disease. Cerebral cortical changes were characterized by a band-like intraparenchymal accumulation of Gaucher cells in lamina IV with an accompanying astrogliosis. In the cerebellum, a focal severe loss of granule cells and a global loss of dentate nucleus neurons was recorded. Milder changes were seen in thalamus and brain stem where perivascular accumulation of Gaucher cells was present in all regions. The cerebral cortical changes resembled those seen in type II Gaucher disease and was much more marked than in the Norrbottnian type III, whereas the changes in the dentate nucleus were more severe than in both type II and type III. The phenotypic variability with different patterns of clinical symptoms and neuropathological changes in neuronopathic Gaucher disease is discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718128     DOI: 10.1007/bf00293959

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  25 in total

1.  Neurological signs in a juvenile form of Gaucher's disease.

Authors:  K M HERRLIN; P O HILLBORG
Journal:  Acta Paediatr       Date:  1962-03       Impact factor: 2.299

Review 2.  Myoclonus in neuronal storage and Lafora diseases.

Authors:  I Rapin
Journal:  Adv Neurol       Date:  1986

3.  Gaucher's disease: neurologic disorder in adult siblings.

Authors:  J D Miller; R McCluer; J N Kanfer
Journal:  Ann Intern Med       Date:  1973-06       Impact factor: 25.391

4.  Juvenile Gaucher's disease with horizontal gaze palsy in three siblings.

Authors:  J H Tripp; B D Lake; E Young; J Ngu; E M Brett
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-05       Impact factor: 10.154

5.  Gaucher disease--Norrbottnian type. I. General clinical description.

Authors:  S Dreborg; A Erikson; B Hagberg
Journal:  Eur J Pediatr       Date:  1980-03       Impact factor: 3.183

6.  Large alterations in ganglioside and neutral glycosphingolipid patterns in brains from cases with infantile neuronal ceroid lipofuscinosis/polyunsaturated fatty acid lipidosis.

Authors:  L Svennerholm; P Fredman; B Jungbjer; J E Månsson; B M Rynmark; K Boström; B Hagberg; L Norén; P Santavuori
Journal:  J Neurochem       Date:  1987-12       Impact factor: 5.372

7.  Increased cerebroside concentration in plasma and erythrocytes in Gaucher disease: significant differences between type I and type III.

Authors:  O Nilsson; G Håkansson; S Dreborg; C G Groth; L Svennerholm
Journal:  Clin Genet       Date:  1982-11       Impact factor: 4.438

8.  Gaucher disease: genetic heterogeneity within and among the subtypes detected by immunoblotting.

Authors:  D Fabbro; R J Desnick; G A Grabowski
Journal:  Am J Hum Genet       Date:  1987-01       Impact factor: 11.025

9.  Gaucher disease--Norrbottnian type (III). Neuropaediatric and neurobiological aspects of clinical patterns and treatment.

Authors:  A Erikson
Journal:  Acta Paediatr Scand Suppl       Date:  1986

10.  Cerebroside-beta-glucosidase activity in Gaucher brain.

Authors:  L Svennerholm; J E Månsson; B Rosengren
Journal:  Clin Genet       Date:  1986-08       Impact factor: 4.438

View more
  13 in total

1.  Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models.

Authors:  Y H Xu; Y Sun; H Ran; B Quinn; D Witte; G A Grabowski
Journal:  Mol Genet Metab       Date:  2010-12-31       Impact factor: 4.797

Review 2.  Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity.

Authors:  N Gupta; I M Oppenheim; E F Kauvar; N Tayebi; E Sidransky
Journal:  Blood Cells Mol Dis       Date:  2010-09-28       Impact factor: 3.039

3.  Glucosylceramide transfer from lysosomes--the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data.

Authors:  M Elleder
Journal:  J Inherit Metab Dis       Date:  2006-11-02       Impact factor: 4.982

4.  Apparent diffusion coefficient vale of the brain in patients with Gaucher's disease type II and type III.

Authors:  Ahmed Abdel Khalek Abdel Razek; Nahed Abd El-Gaber; Ahmed Abdalla; Abeer Fathy; Ahmed Azab; Ashraf Abdel Rahman
Journal:  Neuroradiology       Date:  2009-07-15       Impact factor: 2.804

5.  A model of neuronopathic Gaucher disease.

Authors:  P E Campbell; C M Harris; C M Harris; T Sirimanna; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

6.  Proton MR Spectroscopy of the brain in children with neuronopathic Gaucher's disease.

Authors:  Ahmed Abdel Khalek Abdel Razek; Ahmed Abdalla; Nahed Abdel Gaber; Abeer Fathy; Ahmed Megahed; Tarek Barakat; Mona Abdel Latif Alsayed
Journal:  Eur Radiol       Date:  2013-06-20       Impact factor: 5.315

Review 7.  Enzyme replacement and substrate reduction therapy for Gaucher disease.

Authors:  Elad Shemesh; Laura Deroma; Bruno Bembi; Patrick Deegan; Carla Hollak; Neal J Weinreb; Timothy M Cox
Journal:  Cochrane Database Syst Rev       Date:  2015-03-27

8.  Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease.

Authors:  Mario A Cabrera-Salazar; Matthew Deriso; Scott D Bercury; Lingyun Li; John T Lydon; William Weber; Nilesh Pande; Mandy A Cromwell; Diane Copeland; John Leonard; Seng H Cheng; Ronald K Scheule
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

9.  Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits.

Authors:  Ying Sun; Benjamin Liou; Huimin Ran; Matthew R Skelton; Michael T Williams; Charles V Vorhees; Kazuyuki Kitatani; Yusuf A Hannun; David P Witte; You-Hai Xu; Gregory A Grabowski
Journal:  Hum Mol Genet       Date:  2010-01-04       Impact factor: 6.150

Review 10.  Imiglucerase in the treatment of Gaucher disease: a history and perspective.

Authors:  Patrick B Deegan; Timothy M Cox
Journal:  Drug Des Devel Ther       Date:  2012-04-18       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.